Tramway Ventures

Build With Robots develops robotic systems aimed at enhancing worker safety and efficiency in various industries, including logistics, construction, and entertainment. The company focuses on creating technology that allows robots to work alongside human employees, taking on tasks that are considered dirty, dangerous, or dull, rather than replacing human jobs. Their proprietary disinfection robots utilize fogging technology to effectively sanitize large spaces, helping organizations to mitigate health risks associated with COVID-19 and other airborne particulates. By integrating robotics into the workforce, Build With Robots aims to improve the overall work environment and empower employees while ensuring their safety.

Nob Hill Therapeutics, Inc. is a biotechnology company focused on developing and marketing innovative dry powder nebulizers, specifically designed for the treatment of severe respiratory diseases. Founded in 2016 and based in Fayetteville, Arkansas, the company offers DryNeb, a groundbreaking nebulizer that operates differently from traditional aerosol mist devices. By utilizing a magnetically responsive element to create mechanical collisions in the dispersion chamber, DryNeb ensures consistent and reproducible delivery of medication, independent of the patient's inhalation force. This approach enhances the pulmonary route of drug delivery, which is gaining recognition for its ability to provide targeted, noninvasive administration of drugs directly to the lungs, resulting in improved bioavailability and faster therapeutic effects for patients suffering from various respiratory conditions. Nob Hill Therapeutics has secured exclusive licensing of this technology from the University of New Mexico, positioning itself to address substantial market opportunities in pulmonary drug delivery.

Circular Genomics, established in 2021 with headquarters in Albuquerque, New Mexico, specializes in pioneering precision medicine using circular RNA as novel biomarkers. The company focuses on improving the diagnosis and treatment of neurological and psychiatric conditions by developing RNA-based diagnostic assays, notably for depressive disorders. Their innovative approach enables evidence-based treatments, reducing time to therapeutic response and enhancing physicians' ability to manage psychiatric and neurological diseases effectively.

Vitazi.ai is an early-stage startup located in Santa Fe, New Mexico, specializing in diagnostics technology for the detection of diabetic retinopathy. The company has developed the world's first end-to-end integrated solution that utilizes artificial intelligence to identify this condition. Vitazi.ai provides a customized combination of hardware and software designed to enhance the evaluation of patients, ensuring compliance with quality metrics. By facilitating real-time and accurate disease detection, the company aims to improve reimbursement processes and mitigate the long-term risks associated with preventable vision loss and blindness, benefiting both healthcare professionals and their patients.

Circular Genomics, established in 2021 with headquarters in Albuquerque, New Mexico, specializes in pioneering precision medicine using circular RNA as novel biomarkers. The company focuses on improving the diagnosis and treatment of neurological and psychiatric conditions by developing RNA-based diagnostic assays, notably for depressive disorders. Their innovative approach enables evidence-based treatments, reducing time to therapeutic response and enhancing physicians' ability to manage psychiatric and neurological diseases effectively.

Armonica Technologies is an early-stage medtech company that specializes in developing innovative long-read DNA sequencing technology aimed at precision medicine applications. Named after Benjamin Franklin’s Glass Armonica, the company focuses on a proprietary platform capable of sequencing a complete human genome in minutes. This advanced technology utilizes nanochannels to transport single nucleic acid molecules through nanopores, which are then analyzed through optical readout via Raman spectroscopy. By addressing the limitations of existing sequencing methods, Armonica Technologies enables life science researchers and clinicians to gain a comprehensive view of the genome, providing critical insights into epigenetic modifications. The company's approach is supported by a portfolio of patented and patent-pending technologies licensed from STC.UNM.

WaveDyn Vision is an early-stage medical device company with innovative wavefront diagnostic technology for use in the vision care industry. It plans to leverage its proprietary dynamic wavefront measurement technology to yield new insights into assessing visual performance, advancing treatment options, and improving the quality of life for the visually impaired. The company was founded in 2019 and is based in Albuquerque, New Mexico.

WaveFront Dynamics is a medical device company specializing in advanced wavefront diagnostic technology for the vision care industry. The company develops instruments that assess the visual performance of the human eye by measuring dynamic changes over time, rather than providing a single snapshot. This innovative approach allows for a comprehensive evaluation of the eye, enabling healthcare professionals to enhance treatment planning for complex visual dysfunctions. Through its sophisticated dynamic wavefront measurement capabilities, WaveFront Dynamics aims to improve patient outcomes in ophthalmic care.

BennuBio, Inc. is a technology company based in Albuquerque, New Mexico, that specializes in developing advanced flow cytometry equipment for cell analysis. Founded in 2018, BennuBio focuses on creating instruments capable of sorting and analyzing cells for rare cell applications, which include monitoring blood cells, detecting biomarkers, and facilitating drug discovery. Its flagship product, The Velocyt, enables users to detect rare events such as activated T cells and circulating tumor cells, making it valuable for personalized medicine. The company also offers spheroid generation systems and high-volume sorting systems, along with technical support and applications assistance. By allowing analysis across a wide range of particle sizes and sample volumes, BennuBio aims to enhance the capabilities of healthcare professionals in immuno-oncology treatment and diagnostics.

BennuBio, Inc. is a technology company based in Albuquerque, New Mexico, that specializes in developing advanced flow cytometry equipment for cell analysis. Founded in 2018, BennuBio focuses on creating instruments capable of sorting and analyzing cells for rare cell applications, which include monitoring blood cells, detecting biomarkers, and facilitating drug discovery. Its flagship product, The Velocyt, enables users to detect rare events such as activated T cells and circulating tumor cells, making it valuable for personalized medicine. The company also offers spheroid generation systems and high-volume sorting systems, along with technical support and applications assistance. By allowing analysis across a wide range of particle sizes and sample volumes, BennuBio aims to enhance the capabilities of healthcare professionals in immuno-oncology treatment and diagnostics.

Armonica Technologies is an early-stage medtech company that specializes in developing innovative long-read DNA sequencing technology aimed at precision medicine applications. Named after Benjamin Franklin’s Glass Armonica, the company focuses on a proprietary platform capable of sequencing a complete human genome in minutes. This advanced technology utilizes nanochannels to transport single nucleic acid molecules through nanopores, which are then analyzed through optical readout via Raman spectroscopy. By addressing the limitations of existing sequencing methods, Armonica Technologies enables life science researchers and clinicians to gain a comprehensive view of the genome, providing critical insights into epigenetic modifications. The company's approach is supported by a portfolio of patented and patent-pending technologies licensed from STC.UNM.